Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

Fig. 4

Adjusted difference from placebo in FEV1 AUC0–12 on Day 7 (mITT population). Error bars represent 95% confidence intervals. All p < 0.0001 versus placebo MDI. AUC 0–12 Area under the curve from 0 to 12 h, BID Twice daily, FEV 1 Forced expiratory volume in 1 s, GP Glycopyrronium, LSM Least squares mean, MDI Metered dose inhaler, mITT Modified intent-to-treat, QID Four times daily

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us